Company Profile
Kenvue Stock Price, News & Analysis
- Ticker:
- KVUE
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Stock performance
19.18 USD (-2.49%)
Close
Last updated: August 6, 2026
33.3B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, KVUE closed down 2.49% at $19.18. No new same-company headline was identified in the current news window.
Company overview
Business overview
Kenvue is a consumer health company focused on over-the-counter and personal care brands rather than pharmaceuticals or biotech. Its portfolio is anchored by familiar household products across skin health, oral care, and self-care.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NYSE, Kenvue has a global consumer-health footprint. It is a consumer products company, not a biotech or medtech business.
Business Model Characteristics
The business depends on brand strength, retail distribution, pricing power, and steady consumer demand. Investors watch revenue growth, margin discipline, and portfolio management rather than clinical or regulatory catalysts.
Position Within the Biotechnology Landscape
Kenvue sits outside biotechnology and even outside most healthcare innovation categories. It belongs in consumer health, where brand execution and demand stability matter more than research-driven catalysts.
Future catalysts
Kenvue’s near-term catalysts are consumer-health earnings, margin stabilization, and whether the company can keep proving the post-spin story is getting cleaner. This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile. Better execution here can matter even before a new product or trial headline lands.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Kenvue (KVUE)?
Kenvue (KVUE) most recently closed at 19.18 USD, a -2.49% move versus the previous session.
What is the market cap of Kenvue (KVUE)?
Kenvue currently has a market capitalization of 33.3B USD on BioPharmSignal.
What does Kenvue do?
Kenvue is a consumer health company focused on over-the-counter and personal care brands rather than pharmaceuticals or biotech. Its portfolio is anchored by familiar household products across skin health, oral care, and self-care.
On which exchange is KVUE stock listed?
Kenvue (KVUE) is associated with NYSE, United States, Biopharma.
What is Kenvue?
Kenvue’s near-term catalysts are consumer-health earnings, margin stabilization, and whether the company can keep proving the post-spin story is getting cleaner.
Which conditions is Kenvue targeting with Kenvue?
Kenvue’s near-term catalysts are consumer-health earnings, margin stabilization, and whether the company can keep proving the post-spin story is getting cleaner.
How does Kenvue describe recent progress with Kenvue?
Kenvue’s near-term catalysts are consumer-health earnings, margin stabilization, and whether the company can keep proving the post-spin story is getting cleaner.
What is This?
This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile.